Privia Health Group stock (US74283G1004): Nasdaq-listed healthcare group steady after recent Q1 2026 earnings

Privia Health Group shares were recently quoted at around USD 20.66 on Nasdaq, close to the prior day's close of USD 20.66 on 06/03/2026, according to data from Nasdaq as of that date, keeping the United States-listed healthcare stock broadly stable after its latest results.

The company is headquartered in the United States and trades on the Nasdaq under the ticker PRVA, positioning Privia Health Group firmly within the US healthcare and medical information systems segment for investors following domestic equities.

According to Nasdaq price information for Privia Health Group as of 06/03/2026, the stock closed at USD 20.66, reflecting a decline of 13.3% from USD 23.71 at the beginning of 2026, underscoring how the share price has eased year-to-date despite the recent earnings report, based on figures cited by MarketBeat as of 06/03/2026.

For investors in Germany, Privia Health Group is also available via secondary trading venues such as Tradegate, where prices are typically quoted in euros, offering an additional access point to the US-listed stock for European retail investors.

On the fundamentals side, Privia Health Group reported its Q1 2026 results on 05/07/2026, posting earnings per share of USD 0.19 for the quarter, compared with a consensus estimate of USD 0.08, according to MarketBeat coverage dated 05/07/2026, highlighting the gap between reported EPS and analyst expectations.

The Q1 2026 earnings release on 05/07/2026 confirmed that Privia Health Group remains active in its core healthcare technology and physician practice management activities, with investors closely tracking how the business converts its operating model into per-share earnings over the course of 2026.

MarketBeat data as of 05/07/2026 also indicate that Q1 2026 marked the most recent reported quarter for Privia Health Group, with the next earnings date not yet confirmed by the company but estimated to fall around early August 2026 based on prior-year reporting patterns, giving the market a preliminary timeline for the next set of figures.

From a market performance perspective, the combination of a year-to-date share price decline from USD 23.71 at the start of 2026 to USD 20.66 on 06/03/2026 and a Q1 2026 EPS outcome of USD 0.19 versus a USD 0.08 consensus has created a mixed backdrop where valuation, growth and profitability metrics are being reassessed by investors.

The stock's current level around the low-USD-20 range per share on Nasdaq places Privia Health Group firmly in the mid-cap healthcare segment, with a market capitalization cited around USD 2.6 billion for June 2026 by StockTitan as of 06/2026, which frames the company as a notable but not mega-cap player in the US healthcare technology landscape.

Investor focus in the United States has therefore been directed at whether Privia Health Group can sustain or expand earnings per share beyond the Q1 2026 level of USD 0.19 reported on 05/07/2026, with the next few quarters seen as important for confirming the trajectory of its core operating metrics.

As of: 06/04/2026

By the editorial team - specialized in equity coverage.

Privia Health Group: core business model

Privia Health Group operates a physician enablement and practice management platform in the United States, generating revenue primarily by supporting medical groups and health systems with technology, administrative services and value-based care solutions that share in healthcare cost and quality outcomes.

Industry trends and competitive position

Privia Health Group is part of the broader US healthcare technology and medical information systems sector, which continues to experience structural demand for digital tools that help physicians and health systems manage clinical workflows, billing and value-based contracts, a trend highlighted by market research firms such as IQVIA and Statista through various studies in 2024 and 2025 on healthcare IT adoption.

Within this landscape, Privia Health Group competes with other physician enablement and practice management platforms seeking to align incentives between payers, providers and patients, with investors watching how its technology, scale and partnerships in the United States allow it to capture share in value-based arrangements and population health initiatives compared to peers in the medical information systems space.

Conclusion

Privia Health Group's shares on Nasdaq have been trading around USD 20.66 as of 06/03/2026, while the stock remains below its level at the start of 2026 despite Q1 2026 earnings per share of USD 0.19 reported on 05/07/2026 against a USD 0.08 consensus. For investors in the United States and abroad, the key question over the coming quarters will be how the company converts its physician enablement and value-based care strategy into sustained earnings performance within a competitive healthcare technology and medical information systems sector.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.